| Detailed information |
|---|
| CancerLivER ID | 2306 |
| Biomarker | EPO |
| Biomarker Name/Symbol (given in Publication) | EPO |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential marker for cirrhosis; but not validated on independent dataset |
| Experimental Condition | dysplasia v/s early/late HCC and normal |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in dysplasia v/s control and early/advanced HCC |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 17393520 |
| Type of Biomarker | Diagnostic |
| Pathway | Jak-STAT pathway |
| Cohort | 75 samples (48 patients): Sixty-five samples were obtained from 38 patients with HCV infection representing 13 samples from cirrhotic tissue, 17 dysplastic nodules, and 35 HCCs; samples of normal tissue obtained from the healthy livers of 10 patients undergoing resection for hepatic hemangioma (1), |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | dysplasia v/s early/late HCC and normal |
| Year of Publication | 2007 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |